α1-酸性糖蛋白在挤压综合征相关急性肾损伤诊断与治疗中的作用
该研究在大鼠中比较了1 kg、3 kg、5 kg、8 kg四档挤压力对挤压综合征严重程度的影响:各档挤压力组间生存率与大鼠大腿周径变化没有统计学差异,但5 kg和8 kg组解除挤压后12 h、24 h的血清钾、肌酸激酶、血尿素氮、肌酐、肌红蛋白水平高于1 kg和3 kg组,肾脏、肌肉、肺的组织病理损伤程度随挤压力升高而加重。研究进一步在3 kg或5 kg组筛选出血清差异蛋白,并在0、12、72 h三个时间点验证α1-AGP、NGAL、Haptoglobin表达上调;其中α1-AGP经腹腔注射可减轻挤压综合征诱导的AKI,机制涉及调节TNF-α与IL-6、减少中性粒细胞募集及肾细胞凋亡。作者据此提出α1-AGP可作为预测挤压综合征严重程度的生物标志物及治疗候选分子。
要点
- 大鼠挤压力为5 kg和8 kg时,解除挤压后12 h、24 h血清钾、肌酸激酶、血尿素氮、肌酐、肌红蛋白较1 kg和3 kg组升高,提示重伤组需更密切监测肾功能的趋势
- 不同挤压力组间生存率与大腿周径变化无统计学差异,不能以是否存活或肢体肿胀程度判断挤压综合征严重度
- α1-AGP、NGAL、Haptoglobin在解除挤压后0、12、72 h均表达上调,为候选严重度标志物(动物实验层面)
- 腹腔注射α1-AGP可保护大鼠肾脏免受挤压综合征诱导AKI,机制为调节TNF-α和IL-6、减弱中性粒细胞募集、减少肾细胞凋亡
- 证据来自大鼠模型,α1-AGP的给药剂量、途径、疗程及人体诊断阈值原文均未给出,不能直接转为临床推荐
适用人群与场景
- 研究人群为接受不同挤压力(1 kg、3 kg、5 kg、8 kg)的大鼠模型,非人体研究
- 适用场景(急诊、ICU、院前)与人类纳入/排除人群:原文未提及
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 实验干预:对挤压综合征诱导AKI的大鼠行α1-AGP腹腔注射,可减轻肾损伤,机制为调节TNF-α和IL-6产生、减弱中性粒细胞募集、减少肾细胞凋亡
- α1-AGP的剂量、浓度、给药频次与疗程:原文未提及
- 人体给药途径、目标值及适用条件:原文未提及
红旗征与不能漏的情况
- 5 kg和8 kg挤压力组解除挤压后12 h、24 h出现血清钾、肌酸激酶、血尿素氮、肌酐、肌红蛋白升高,并伴肾脏、肌肉、肺组织病理损伤加重,提示高挤压力伤员需警惕挤压综合征相关AKI及多器官损伤
- 原文未给出针对上述情况的具体处理措施
研究设计与关键结果
- 研究类型:大鼠实验研究(动物模型),中心数与样本量原文未提及
- 干预与对照:按1 kg、3 kg、5 kg、8 kg挤压力分组比较;另在3 kg或5 kg组与对照组间比较血清蛋白谱
- 主要结果:各挤压力组间生存率及大腿周径变化无统计学差异;5 kg、8 kg组解除挤压后12 h、24 h血清钾、肌酸激酶、血尿素氮、肌酐、肌红蛋白高于1 kg、3 kg组;组织病理损伤程度随挤压力增加而加重
- 蛋白组学:3 kg或5 kg组在解除挤压后0、12、72 h三个时间点共76种蛋白改变(20种上调、56种下调);α1-AGP、NGAL、Haptoglobin经验证表达上调
证据类型、等级与局限
- 证据类型:动物实验研究(大鼠),非RCT、非人体研究
- 证据等级或推荐强度:原文未提及
- 局限:仅在大鼠模型中进行,挤压力以kg表示,结论不能直接外推至人类;α1-AGP的剂量、疗程及人体诊断阈值均未报告
对床旁实践的改变
- 不改变现有急诊/ICU挤压综合征处置流程:α1-AGP目前仅为动物实验中的候选标志物与治疗分子,尚不能用于人体诊断或治疗
- 可提示:对高挤压力、解除挤压后12–24 h出现血钾、肌酸激酶、肌酐、肌红蛋白升高的伤员,应警惕AKI与多器官损伤(依据大鼠结果,需人体研究验证)
- 常见陷阱:不能因生存率或肢体肿胀程度无差异而低估挤压伤严重度;不能将动物实验中的挤压力数值或蛋白变化直接当作人体决策阈值
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Crush syndrome (CS) is the most common cause of deaths following earthquakes and other disasters. The pathogenesis of CS has yet to be fully elucidated. Thus, clinical choice of ideal drug treatments for CS remains deficient.
METHODS AND RESULTS: In this study, we first evaluated the relation between extrusion force and the severities of CS. Rats were exposed to different extrusion forces: 1 kg, 3 kg, 5 kg, and 8 kg, respectively. Survival rates, crushed muscle tissue edema, serum biochemical parameters, and histopathological staining were used to assess severity. Our results showed that there were no statistical differences in survival rate or changes in thigh circumference among the different extrusion forces groups. However, serum levels of potassium, creatine kinase, blood urea nitrogen, creatinine, and myoglobin were elevated at 12- and 24-h post-decompression in 5 kg and 8 kg groups, compared with 1 kg and 3 kg groups. Histopathological staining demonstrated that the degree of organ damage to kidney, muscle, and lung tissues correlated with increasing extrusion force. We next analyzed changes in serum protein profiles in 3 kg or 5 kg extrusion pressure groups. A total of 76 proteins (20 upregulated, 56 downregulated) were found to be altered at all three time points (0, 12, and 72 h) post-decompression, compared with the control group. Three common upregulated proteins alpha-1-acid glycoprotein (α1-AGP), neutrophil gelatinase-associated lipocalin (NGAL), and Haptoglobin were selected for validation of increased expression. α1-AGP was explored as a treatment for CS-induced acute kidney injury (AKI). Intraperitoneal injection of α1-AGP protected kidneys from CS-induced AKI by regulating TNF-α and IL-6 production, attenuating neutrophil recruitment, and reducing renal cell apoptosis.
CONCLUSION: Our findings demonstrated that the severity of crush injury is causally related to extrusion pressure and increase in blood serum markers. Our identification of the biomarker and treatment candidate, α1-AGP, suggests its implication in predicting the severity of CS and its use as a mediator of CS-induced AKI, respectively.
参考来源
- Lv Q, Long M, Wang X, et al. The Role of Alpha-1-Acid Glycoprotein in the Diagnosis and Treatment of Crush Syndrome-Induced Acute Kidney Injury. Shock. 2021. PMID: 34313253. doi:10.1097/SHK.0000000000001839
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。